MedTrace Logo

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

NCT02357342 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-06-22

Study results available
· View outcomes & findings →

Summary

Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous AntiVEGF treatment.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Sirolimus

intravitreal injection

DRUG

Standard of Care intravitreal injections of anti-VEGF

intravitreal injections of anti-VEGF

Sponsors & Collaborators

  • Maturi, Raj K., M.D., P.C.

    lead INDIV

Principal Investigators

  • Raj K Maturi, MD · Raj K. Maturi, MD, PC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02357342 on ClinicalTrials.gov